Founder and CEO, Graphen, Inc.
Talk: Among Us and Beyond Human: AI for the Well-Being of Mankind
Is now the Newton Moment in Biomedicine? In May 2020, the ABI Medical White Paper listed Graphen and Google as two companies that would have a significant impact on drug development, which will be no longer based on try-and-error, but more deterministic, because of AI.
Graphen Drugomics developed an AI platform of more than 100 tools for almost the entire process of drug design, e.g., target identification, protein function & structure prediction, binding prediction, ADME prediction, genomic reasoning, etc. We created All-in-One processes and AI agents to actively design new drugs. Our strong pipeline of more than 10 drugs for popular diseases, including OA knee disease and diabete kidney disease, demonstrated its effectiveness and advantage.
Graphen Agents & Robotics creates Digital Human and Humanoid Robots with potential Artificial General Intelligence (AGI) to assist daily life. With population significantly shrinking in the developed countries, this is a big urgent need. For instance, Taiwan’s birth number shrank 50% in the last 10 years. Many East Asian countries are in a similar trend. No matter in home or in business, shortage of caregiver and labor is tremendous.
Furthermore, I shall demo how the multi-agent-based Graphen AI Co-Doctors are used in hospitals and AI Learning for education.
Impact of AI is everywhere. Hope our effort can help assist life and save live, making human beings happier and healthier.
About:
Dr. Ching-Yung Lin (林清詠) founded Graphen Group in 2017 and serves as CEO. Graphen's mission is to develop State-of-the-art AI or the well-being of mankind. A 2024 survey ranked Graphen as the Top #9 AI company in the world. Graphen is headquartered in New York City and has subsidiaries in Taipei, Tokyo, Singapore, and Hong Kong.
Dr. Lin has been an adjunct professor in Columbia University since 2005. He was the Chief Scientist at IBM Corp (2015-17) and founder of the Network Science and Machine Intelligence Group at the Watson Research Center, where he worked for 17 years. He has also been an adjunct professor at New York University (2014) and the University of Washington (2003-2009). He was appointed an IEEE Fellow in 2011. His interest has always been in artificial intelligence that enables full-brain functionality through fundamental R&D breakthroughs. In the past 25 years, he has led tens of large-scale global AI projects, deployed in the United States, Europe, China, Japan, Russia and Southeast Asia.
Dr. Lin has been an invited keynote speaker at more than 100 conferences, including serving as a co-speaker with the White House Chief Data Scientist at the 2015 American Medical Association Annual Meeting. He is the author or co-author of more than 200 publications, holds 75+ patents, cited approximately 13,000 times, and has an h-index of 57. Dr. Lin's work has received 7 best paper awards and been featured four times in BusinessWeek magazine, including as a cover story in May 2009. In 2010, the IBM Career Review selected Dr. Lin as "a scientist most likely to have the greatest scientific impact on IBM and the world."
